Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

被引：0
|
作者：
Charalampos Charalampous
Utkarsh Goel
Prashant Kapoor
Moritz Binder
Francis K. Buadi
Joselle Cook
David Dingli
Angela Dispenzieri
Amie L. Fonder
Morie A. Gertz
Wilson Gonsalves
Suzanne R. Hayman
Miriam A. Hobbs
Yi L. Hwa
Taxiarchis Kourelis
Martha Q. Lacy
Nelson Leung
Yi Lin
Rahma Warsame
Robert A. Kyle
S. Vincent Rajkumar
Shaji K. Kumar
机构：
[1] Mayo Clinic,Division of Hematology, Department of Internal Medicine
[2] Mayo Clinic,Division of Nephrology and Hypertension, Department of Internal Medicine
来源：
Blood Cancer Journal | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Predictors of Second-Line Treatment Choice with Triplet Therapy in Routine Care Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Romanus, Dorothy
    Jhaveri, Mehul
    Labotka, Richard
    Henk, Henry
    Seal, Brian
    BLOOD, 2015, 126 (23)
  • [42] Real world experience of Daratumumab monotherapy as fourth line therapy in relapsed/refractory myeloma
    Taube, J. B.
    Chavda, S.
    Popat, R.
    Papanikolaou, X.
    Cheesman, S.
    Sachchithanantham, S.
    Mahmood, S.
    Mehta, A.
    D'Sa, S.
    Kyrioakou, C.
    Wechalekar, A.
    Yong, K.
    Rabin, N.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 99 - 99
  • [43] Daratumumab-based three drug regimens for high-risk multiple myeloma: A meta-analysis.
    Farooqui, Arafat Ali
    Tariq, Muhammad
    Nabeel, Shaha
    Ashraf, Aqsa
    Ahmed, Zahoor
    Faisal, Muhammad Salman
    Din, Mohammad Ammad Ud
    Shahab, Zartashia
    Setarehaseman, Alireza
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Second-line therapy in young patients with relapsed or refractory orbital rhabdomyosarcoma
    Zloto, Ofira
    Minard-Colin, Veronique
    Boutroux, Helene
    Brisse, Herve J.
    Levy, Christine
    Kolb, Frederic
    Bolle, Stephanie
    Carton, Matthieu
    Helfre, Sylvie
    Orbach, Daniel
    ACTA OPHTHALMOLOGICA, 2021, 99 (03) : 334 - 341
  • [45] Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study
    Sunami, Kazutaka
    Murakami, Hiroyuki
    Tagashira, Hisashi
    Ueda, Hiroko
    Moriyama, Takashi
    Ishikawa, Tatsunori
    Yoshioka, Takanori
    Makita, Masanori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (12) : 2151 - 2157
  • [46] Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
    Hoylman, Emily
    Brown, Anna
    Perissinotti, Anthony J.
    Marini, Bernard L.
    Pianko, Matthew
    Ye, Jing Christine
    Campagnaro, Erica
    Nachar, Victoria R.
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 691 - 698
  • [47] Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study
    Kazutaka Sunami
    Hiroyuki Murakami
    Hisashi Tagashira
    Hiroko Ueda
    Takashi Moriyama
    Tatsunori Ishikawa
    Takanori Yoshioka
    Masanori Makita
    International Journal of Clinical Oncology, 2020, 25 : 2151 - 2157
  • [48] Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma
    Chehab, Sarah
    Panjic, Elyse Hall
    Gleason, Charise
    Lonial, Sagar
    Nooka, Ajay K.
    FUTURE ONCOLOGY, 2018, 14 (30) : 3111 - 3121
  • [49] ECONOMIC EVALUATION OF DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Salazar, A.
    Guirant Corpi, L.
    Aguirre, A.
    Herrera, M.
    Chacon, C.
    VALUE IN HEALTH, 2018, 21 : S254 - S254
  • [50] Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma
    Kareem, Syeda Saba
    Viswanathan, Neena
    Sahebjam, Solmaz
    Tran, Nam D.
    Gatewood, Tyra
    Tobon, Katherine
    Baz, Rachid
    Pina, Yolanda
    Shain, Kenneth H.
    Mokhtari, Sepideh
    ONCOTARGETS AND THERAPY, 2022, 15 : 953 - 962
12345